



Pfizer Limited

The Capital, 1802 / 1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

July 13, 2018

Mr. Subhash Purohit,
Assistant Manager
Listing Compliance Department
BSE Limited, 24th Floor,
P J Towers, Dalal Street
Mumbai - 400001

Dear Sir,

Sub: Verification – July 13, 2018 - Pfizer Ltd. (500680)

This refers to your email dated July 13, 2018 received by us at 4.21 pm seeking clarification on the news item captioned "Pfizer's Tamil Nadu Injectable Plant gets 11 USFDA observations", which appeared on www.business-standard.com on July 12, 2018.

We wish to inform you that the above news item does not relate to Pfizer Limited, India. The said news item appears to be related to the export oriented manufacturing facility of Pfizer Healthcare India Pvt. Ltd. (Earlier known as Hospira Healthcare India Pvt. Ltd.), an unlisted Indian subsidiary of Pfizer Inc., USA. Hence, Pfizer Limited India will not be able to comment on the said news item.

Rest assured, if and when Pfizer Limited makes any announcement regarding any material development in respect of our business we will ensure that we continue to follow the mandates procedure of informing Stock Exchanges in a timely manner, so as to ensure uniform and simultaneous disclosure to all the investors.

Thanking you,

Yours truly,
For PFIZER LIMITED

Prajeet Nair
Company Secretary